Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced financial results for the fourth quarter and fiscal year (FY) 2009 ended April 30, 2009. Total revenues for the fourth quarter of FY 2009 increased to $7,867,000, compared to $901,000 for the comparable quarter in FY 2008. Total revenues for the 2009 fiscal year increased approximately 200% from $6,093,000 in FY 2008 to $18,151,000 in FY 2009, primarily from increased contract manufacturing revenues generated by Avid Bioservices, the company's wholly owned subsidiary, and increased revenues derived from the company's R&D contract with the federal government.

Avid generated manufacturing revenues of $5,009,000 for the fourth quarter of FY 2009, compared to $751,000 for the comparable prior year quarter, while full year FY 2009 manufacturing revenues more than doubled to $12,963,000, up from $5,897,000 in FY 2008. The increase in Avid revenues reflects increased manufacturing services provided to third-party customers during the quarter and the full fiscal year. In addition to manufacturing revenues, during FY 2009 Peregrine generated revenues from services provided under its government contract with the U.S. Defense Threat Reduction Agency (DTRA) to evaluate bavituximab as a potential broad spectrum treatment for viral hemorrhagic fever infections. Government contract revenues were $2,683,000 for the fourth quarter of FY 2009 and $5,013,000 for the 2009 fiscal year. Peregrine's work under the DTRA contract began during FY 2009, so there are no comparable figures for FY 2008.

Total costs and expenses in the fourth quarter of FY 2009 were $11,239,000, compared to $7,198,000 in the fourth quarter of FY 2008. Increa
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... December 26, 2014 Cooking and ... 3.1 out of 5. This score reflects slightly positive ... of product specialization, low switching costs and a low ... by the low availability of substitutes for cooking and ... of steel and aluminum, key inputs in the production ...
(Date:12/26/2014)... Seattle, WA (PRWEB) December 26, 2014 ... to deal with personal injury claim issues and phone ... their recently released an article featuring their free ... The exceptionally helpful eBook on pedestrian and bicycle auto ... injury attorney is fully capable of professionally handling their ...
(Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... , SINGAPORE, June 4 /PRNewswire-Asia/ ... industry will have a unique platform to gain business ... and Congress,2009. According to market analysts, the medical tourism ... market alone will generate revenue,of more than US$4.4 billion ...
... 4 Abbott (NYSE: ABT ) and ... New Drug Application (NDA) to the U.S. Food and ... treatment of mixed dyslipidemia, a combination of two or ... cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). ...
... Sheets: GOHE) announced today that the company has entered into a ... of a source of high pH water from a premier aquifer. ... annually of this healthy water. , , The water has ... significant natural anti oxidants. , , Charlie Caudle, CEO of ...
... June 4 /PRNewswire/ -- US Oncology, ... aggregate principal amount of senior secured notes to qualified institutional ... of 1933, as amended (the "Securities Act") and outside the ... Act. , , The company plans to use the ...
... 4 Prescribing Reference LLC is pleased to announce that the ... medical professionals as a free download for ... www.empr.com/download ). The MPR Mobile & Desktop Edition ... Microsoft Vista. , , For over 24 years, medical professionals ...
... Advisors, MISSION Skincare(TM) , , NEW YORK, June 4 ... skincare products, is pleased to announce that Brian B. Adams, ... of the world,s most-esteemed athletes as the latest addition to ... of the Board of Advisors, Dr. Adams will play an ...
Cached Medicine News:Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 2Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 4Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 5Health News:Go Healthy Enters Letter of Intent to Acquire Premium Water Source 2Health News:US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering 2Health News:MPR Drug Database Available as a Free Download for Mobile Devices, Including BlackBerry and Palm 2Health News:Dr. Brian B. Adams to Join the 'MISSION' 2Health News:Dr. Brian B. Adams to Join the 'MISSION' 3
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... YORK and LONDON , ... global orthopedic industry are expected to grow at an ... in terms of value and volume. Hip, knee and ... developed world while in emerging economies they have a ... rates are challenging the use of composites. Non-metallic orthopedic ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 25 LigoCyte Pharmaceuticals, Inc. , a ... today announced positive results from a Phase I/II ... vaccine candidate. Baylor College of Medicine,s Robert Atmar, ... the trial via an oral presentation at the ...
... Oct. 25 Express Scripts, Inc. (Nasdaq: ... following investor conferences in November:Oppenheimer 21st Annual Healthcare Conference ... Suisse 2010 Healthcare Conference on Wednesday, November 10, 2010 ... 7th Annual Healthcare Conference on Tuesday, November 16, 2010 ...
Cached Medicine Technology:Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 2Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 3Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 4Express Scripts to Present at Investor Conferences in November 2
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
... CKX microscopes utilize the infinity-corrected ... and operability in cell checking. ... inverted microscope suited to routine ... fields--from tissue culture and embryology ...
... was designed from the ground-up with ergonomic ... height and most adjustable observation tube on ... that every user can adjust the microscope ... flexibility helps the operator maintain an upright, ...
Medicine Products: